The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

March 18, 2021

Study Completion Date

September 29, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

HX009

During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.

Trial Locations (1)

2217

St George Private Hospital, Kogarah

All Listed Sponsors
lead

Waterstone Hanxbio Pty Ltd

INDUSTRY

NCT04097769 - The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter